Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus.
CONCLUSIONS: LY IGlar and IGlar have similar immunogenicity profiles; anti-insulin glargine antibody levels were low for both treatments with no observed effect on efficacy and safety outcomes.
PMID: 26434665 [PubMed - as supplied by publisher]
Source: Diabetes Metab - Category: Endocrinology Authors: Ilag LL, Deeg MA, Costigan T, Hollander P, Blevins TC, Edelman SV, Konrad RJ, Ortmann RA, Pollom RK, Huster WJ, Zielonka JS, Prince MJ Tags: Diabetes Obes Metab Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Insulin | Lantus | Statistics | Study